Ten consecutive children with high risk leukemia have been submitted to UCB transplant from unrelated HLA mismatched donors. All patients received an identical regimen for conditioning and GVHD prophylaxis. The median dose of viable nucleated cells infused was 2.6 x 10(6)/kg b.w. Among the nine patients evaluable for engraftment the hematopoiesis was of full donor origin in six patients and autologous in three. At a median follow-up of 9 months, six of nine (67%) patients are alive in CR
Umbilical cord blood (UCB) transplant from unrelated mismatched donor in patients with high risk (HR) leukemia / Iori, Ap; Screnci, M; Guglielmi, Cesare; Mengarelli, A; Carmini, D; Testi, Anna Maria; Moleti, Ml; Cimino, Giuseppe; Perrone, P; Laurenti, L; Elia, L; Boecklin, F; Romano, A; Vulcano, F; De Felice, L; Arcese, William. - In: BONE MARROW TRANSPLANTATION. - ISSN 0268-3369. - 22:(1998), pp. 75-75.
Umbilical cord blood (UCB) transplant from unrelated mismatched donor in patients with high risk (HR) leukemia.
GUGLIELMI, Cesare;TESTI, Anna Maria;CIMINO, Giuseppe;ARCESE, William
1998
Abstract
Ten consecutive children with high risk leukemia have been submitted to UCB transplant from unrelated HLA mismatched donors. All patients received an identical regimen for conditioning and GVHD prophylaxis. The median dose of viable nucleated cells infused was 2.6 x 10(6)/kg b.w. Among the nine patients evaluable for engraftment the hematopoiesis was of full donor origin in six patients and autologous in three. At a median follow-up of 9 months, six of nine (67%) patients are alive in CRI documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
